Belumosudil-associated neurological adverse events: evidence from FAERS and experimental validation.
- 1Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215123, China.
- 2Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215123, China. [email protected].
Abstract
Purpose
Belumosudil, a first-in-class ROCK2 inhibitor, was approved by the U.S. Food and Drug Administration in 2021 for the treatment of chronic graft-versus-host disease (cGVHD). This study aimed to evaluate the real-world safety profile of belumosudil and investigate its potential neurological adverse effects (AEs).Methods
Adverse events (AEs) related to belumosudil were extracted from the FDA Adverse Event Reporting System (FAERS) from Q3 2021 to Q2 2025. Signal detection was performed using four disproportionality methods: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Time-to-onset was analyzed using the Weibull distribution. Network pharmacology analysis, including target prediction, disease-gene collection, protein-protein interaction network construction, and GO/KEGG enrichment analyses, was conducted to explore potential targets and pathways associated with neurotoxicity. Cellular experiments in SH-SY5Y cells and primary neurons were performed to validate the predicted neurotoxic effects.Results
A total of 2225 cases involving belumosudil were identified, comprising 5852 AE reports. In addition to known label-listed AEs such as fatigue, nausea, infection, pneumonia, and rash, several potential unlisted AEs were detected, including stomatitis, dry eye, cataract, and neurological events such as neuropathy peripheral, depressed mood, and emotional disorder. The median onset time was 78.5 days (IQR 23-169.5), with most events occurring within the first 30 days. Network pharmacology identified 46 overlapping targets, and enrichment analysis highlighted pathways related to neuronal function and survival. Furthermore, in vitro experiments demonstrated that belumosudil induced dose-dependent neuronal injury in SH-SY5Y cells and impaired neurite outgrowth in primary neurons, which may involve modulation of the AKT signaling pathway.Conclusion
This study provides a real-world safety evaluation of belumosudil and identifies potential unlisted neurological AEs. Integration of network pharmacology and neuronal experiments provides preliminary support for the potential biological relevance of these findings and highlights the need for further monitoring of neurological AEs.
Related
- Integrative genomics and experimental validation identify a mechanosensitive gene signature associated with colorectal cancer liver metastasis
- Autonomous AI research agents in pancreatic ductal adenocarcinoma immunology: from multimodal evidence to experimental validation
- Integrated Transcriptomic Analysis and Experimental Validation Identify ATF3 as a Mesangial Cell-Associated Candidate Regulator in IgA Nephropathy
- Integrated Network Pharmacology and Experimental Validation Implicate AKT1‐Associated Signaling in the Protective Effects of Panax notoginseng Against Pulmonary Arterial Hypertension
- Screening and experimental validation of prognostic genes associated with B cell exhaustion in lung adenocarcinoma based on ordinary transcriptome data.
BibTeX
@article{zhou2026belumosudilassociated,
title = {{Belumosudil-associated neurological adverse events: evidence from FAERS and experimental validation.}},
author = {Zeng-Hui Zhou and Yi-Xuan Wang and Jing-Jing Ma and Jin Wu},
journal = {BMC neurology},
year = {2026},
month = jul,
doi = {10.1186/s12883-026-05032-y},
url = {https://europepmc.org/article/MED/42919262},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Belumosudil-associated neurological adverse events: evidence from FAERS and experimental validation.
AU - Zeng-Hui Zhou
AU - Yi-Xuan Wang
AU - Jing-Jing Ma
AU - Jin Wu
PY - 2026
DA - 2026/07/01
JO - BMC neurology
DO - 10.1186/s12883-026-05032-y
UR - https://europepmc.org/article/MED/42919262
AB - Purpose Belumosudil, a first-in-class ROCK2 inhibitor, was approved by the U.S. Food and Drug Administration in 2021 for the treatment of chronic graft-versus-host disease (cGVHD). This study aimed to evaluate the real-world safety profile of belumosudil and investigate its potential neurological adverse effects (AEs).Methods Adverse events (AEs) related to belumosudil were extracted from the FDA Adverse Event Reporting System (FAERS) from Q3 2021 to Q2 2025. Signal detection was performed using four disproportionality methods: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Time-to-onset was analyzed using the Weibull distribution. Network pharmacology analysis, including target prediction, disease-gene collection, protein-protein interaction network construction, and GO/KEGG enrichment analyses, was conducted to explore potential targets and pathways associated with neurotoxicity. Cellular experiments in SH-SY5Y cells and primary neurons were performed to validate the predicted neurotoxic effects.Results A total of 2225 cases involving belumosudil were identified, comprising 5852 AE reports. In addition to known label-listed AEs such as fatigue, nausea, infection, pneumonia, and rash, several potential unlisted AEs were detected, including stomatitis, dry eye, cataract, and neurological events such as neuropathy peripheral, depressed mood, and emotional disorder. The median onset time was 78.5 days (IQR 23-169.5), with most events occurring within the first 30 days. Network pharmacology identified 46 overlapping targets, and enrichment analysis highlighted pathways related to neuronal function and survival. Furthermore, in vitro experiments demonstrated that belumosudil induced dose-dependent neuronal injury in SH-SY5Y cells and impaired neurite outgrowth in primary neurons, which may involve modulation of the AKT signaling pathway.Conclusion This study provides a real-world safety evaluation of belumosudil and identifies potential unlisted neurological AEs. Integration of network pharmacology and neuronal experiments provides preliminary support for the potential biological relevance of these findings and highlights the need for further monitoring of neurological AEs.
SN - 1471-2377
ER -